Cocoa Flavanols and Exercise Capacity
Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Dec 13, 2010
Trial Information
Current as of October 02, 2025
Completed
Keywords
ClinConnect Summary
13 participants (highly-trained cyclist, accustomed to exercise testing on ergometers will be enrolled (VO2max\>50 ml/kg, FMD \>5%, non-smokers, no medication, no diseases, age 20-36, male).
Baseline Testing:
Participants will perform a baseline testing consisting of an ergometric test with a step-wise increase of workload until exhaustion to determine lactate anaerobic threshold and cardio-pulmonary exercise capacity. Vascular function is monitored by Doppler Ultrasound.
In a second test, participants will perform a time trial (goal: as fast as possible)
Flavanol intervention Participa...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • highly trained cyclists (VO2 peak \> 50 ml/kg bodyweight)
- • refrain from cocoa ingestion during trial
- • training continued throughout testing
- • \> 20 years
- • male
- Exclusion Criteria:
- • \> 36 years
- • poor endothelial function
- • acute infection
- • any chronic heart or pulmonary disease
- • arrhythmias
- • acute or chronic renal failure
- • smokers
- • cardio-vascular risk factors : diabetes mellitus, hypertension, hyperlipidemia
- • intake of nutrition supplements (l-arginine, creatinine)
- • intake of WADA listed doping substances
About Heinrich Heine University, Duesseldorf
Heinrich-Heine University Düsseldorf is a leading academic institution dedicated to advancing medical research and education. Renowned for its innovative approach to healthcare and interdisciplinary collaboration, the university plays a pivotal role in clinical trials aimed at improving patient outcomes and translating scientific discoveries into clinical practice. With a robust infrastructure and a commitment to ethical standards, Heinrich-Heine University fosters an environment that supports cutting-edge research initiatives, contributing significantly to the advancement of medical knowledge and therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Duesseldorf, Nrw, Germany
Patients applied
Trial Officials
Tienush Rassaf, MD, PhD
Principal Investigator
Heinrich Heine University Düsseldorf, NRW, Germany
Malte Kelm, MD, PhD
Study Chair
Heinrich Heine University Düsseldorf, NRW, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials